$CLPT

BURNETT JOSEPH sold $388K of CLPT

BURNETT JOSEPH (CEO and President) sold 20,000 shares of ClearPoint Neuro, Inc. (CLPT) at $19.38 ($0.39M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BURNETT JOSEPH
Published Jul 1, 2026, 10:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 10:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLPT
Neutral
medium confidence
Mentioned
$CLPT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale (20,000 shares at $19.38) and the post-transaction holdings, which can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

This is a fresh insider-sale datapoint; it may matter for short-term sentiment but is unlikely to drive a fundamental repricing alone.

03

What to watch

Traders may overreact to the headline sale size; the key nuance is the 10b5-1 pre-arrangement, which often dampens signal quality.

Relevance 3/10Novelty 6/10Timing: today’s SEC Form 4 disclosure (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction for ClearPoint Neuro, Inc. (CLPT) by CEO/President Joseph Burnett.

Company-level read

Ticker impact

$CLPTNeutralMedium confidence
Context

ClearPoint Neuro CEO Joseph Burnett sold 20,000 shares in an open-market transaction at $19.38 on 2026-06-29, per Form 4.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source Form 4 showing a sizable sale, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • ClearPoint Neuro, Inc.

    Subject of the Form 4 insider sale disclosed in the article.

  • Joseph Burnett

    CEO and President who sold 20,000 shares under a 10b5-1 plan.

Related articles

$CLPTMed

ClearPoint Neuro, Inc. (CLPT): Results of Operations and Financial Condition

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 clpt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, In